

Talking About ELREXFIO With Your Doctor:

A Comprehensive Discussion Guide

This guide will provide you with questions to ask your healthcare team to see if ELREXFIO is right for you.

Get the conversation started by bringing this guide to your doctor's office on your tablet or mobile device. If you prefer, you can also print it out.



What is ELREXFIO?

ELREXFIO is a prescription medication used to treat adults with multiple myeloma who:

- have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody to treat their multiple myeloma, **and**
- their cancer has come back or did not respond to prior treatment

ELREXFIO was approved based on patient responses and durability of response. There are ongoing studies to confirm its clinical benefit. It is not known if ELREXFIO is safe and effective in children.

Please see **Important Safety Information** on pages 5-7, as well as the full **Prescribing Information**, including **BOXED WARNING**, and **Medication Guide**.

Getting to Know ELREXFIO

1. Is ELREXFIO right for me based on my treatment history and goals?
2. If ELREXFIO isn't right for me now, will it be an option for me in the future?

ELREXFIO Clinical Benefits

3. How effective was ELREXFIO in clinical trials?
4. How long could results with ELREXFIO last?
5. How quickly did people respond to ELREXFIO in the clinical trial?

How ELREXFIO Works

6. What kind of treatment is ELREXFIO?
7. How does ELREXFIO work?

Please see Important Safety Information on pages 5-7, as well as the full [Prescribing Information](#), including **BOXED WARNING**, and [Medication Guide](#).

Possible Side Effects

8. What side effects might I experience on ELREXFIO?
9. When should I tell you if I experience side effects?
10. What can be done to help manage potential side effects?
11. What is the ELREXFIO Risk Evaluation and Mitigation Strategy (REMS) program and what does it mean for me?

Dosing and Administration

12. How is ELREXFIO administered?
13. Where and how often will I receive ELREXFIO treatment?
14. When is every-other-week dosing generally available for people taking ELREXFIO?

Please see Important Safety Information on pages 5-7, as well as the full [Prescribing Information](#), including **BOXED WARNING**, and [Medication Guide](#).

Considerations During Treatment

15. Will ELREXFIO interfere with other medications I'm taking?

16. Will I need to change my diet during ELREXFIO treatment?

17. Can I continue to take over-the-counter medicines, vitamins, or herbal supplements while on ELREXFIO?

Support and Resources

18. Will my insurance cover ELREXFIO?

19. What resources are available to help with financial support for ELREXFIO?

20. What other support is available during treatment?

Please see Important Safety Information on pages 5-7, as well as the full [Prescribing Information](#), including **BOXED WARNING**, and [Medication Guide](#).

IMPORTANT SAFETY INFORMATION

ELREXFIO may cause side effects that are serious, life-threatening, or can lead to death, including cytokine release syndrome (CRS) and neurologic problems. CRS is common during treatment with ELREXFIO.

Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS or neurologic problems, including:

- fever of 100.4°F (38°C) or higher
- trouble breathing
- chills
- dizziness or light-headedness
- fast heartbeat
- headache
- increased liver enzymes in your blood
- agitation, trouble staying awake, confusion or disorientation, or seeing or hearing things that are not real (hallucinations)
- trouble speaking, thinking, remembering things, paying attention, or understanding things
- problems walking, muscle weakness, shaking (tremors), loss of balance, or muscle spasms
- numbness and tingling (feeling like “pins and needles”)
- burning, throbbing, or stabbing pain
- changes in your handwriting

Due to the risk of CRS, you will receive ELREXFIO on a “step-up” dosing schedule and should be hospitalized for 48 hours after the first “step-up” dose and for 24 hours after the second “step-up” dose of ELREXFIO.

- For your first dose, you will receive a smaller “step-up” dose of ELREXFIO on day 1
- For your second dose, you will receive a larger “step-up” dose of ELREXFIO, which is usually given on day 4 of treatment
- For your third dose, you will receive the first full “treatment” dose of ELREXFIO, which is usually given on day 8

If your dose of ELREXFIO is delayed for any reason, you may need to repeat step-up dosing. Before each dose of ELREXFIO you receive during the step-up dosing schedule, you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicines to help reduce your risk of CRS with future doses.

ELREXFIO is available only through the ELREXFIO Risk Evaluation and Mitigation Strategy (REMS) Program due to the risk of CRS and neurologic problems. You will receive an ELREXFIO Patient Wallet Card from your healthcare provider. **Carry the ELREXFIO Patient Wallet Card with you at all times and show it to all of your healthcare providers.** The ELREXFIO Patient Wallet Card lists signs and symptoms of CRS and neurologic problems. **Get medical help right away if you develop any of the symptoms listed on the ELREXFIO Patient Wallet Card.** You may need to be treated in a hospital.

Please see full [Prescribing Information](#), including **BOXED WARNING**, and [Medication Guide](#).

IMPORTANT SAFETY INFORMATION (CONTINUED)

Before taking ELREXFIO, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection
- are pregnant or plan to become pregnant. ELREXFIO may harm your unborn baby. **Females who are able to become pregnant** should have a pregnancy test before starting treatment with ELREXFIO and should use effective birth control during treatment and for 4 months after the last dose of ELREXFIO. Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with ELREXFIO
- are breastfeeding or plan to breastfeed. It is not known if ELREXFIO passes into your breast milk. Do not breastfeed during treatment and for 4 months after your last dose of ELREXFIO

Tell your healthcare provider about all of the medications you take, including prescription and over-the-counter medications, vitamins, and herbal supplements.

Do not drive, operate heavy or potentially dangerous machinery, or do other dangerous activities during treatment with ELREXFIO:

- for 48 hours after completing each of the 2 doses of ELREXFIO that are part of the “step-up dosing schedule” and your first full treatment dose, **and**
- at any time during treatment with ELREXFIO if you develop any new neurologic symptoms, such as dizziness, confusion, shaking (tremors), sleepiness, or any other symptom that impairs consciousness, until the symptoms go away

Infections: Upper respiratory tract infection and pneumonia are common during treatment with ELREXFIO. ELREXFIO can cause bacterial and viral infections that are severe, life-threatening, or that may lead to death.

- Your healthcare provider may prescribe medications for you to help prevent infections and treat you as needed if you develop an infection during treatment with ELREXFIO
- Tell your healthcare provider right away if you develop any signs or symptoms of an infection during treatment with ELREXFIO, including: fever of 100.4°F (38°C) or higher, chills, cough, shortness of breath, chest pain, sore throat, pain during urination, or feeling weak or generally unwell
- People with active infections should not start ELREXFIO

Decreased white blood cell counts: Decreased white blood cell counts are common during treatment with ELREXFIO and can also be severe. A fever can occur with low white blood cell counts and may be a sign that you have an infection. Your healthcare provider will treat you as needed.

Please see full [Prescribing Information](#), including **BOXED WARNING**, and [Medication Guide](#).

IMPORTANT SAFETY INFORMATION (CONTINUED)

Liver problems: ELREXFIO can cause increased liver enzymes and bilirubin in your blood. These increases can happen with or without you also having CRS. Tell your healthcare provider if you develop any signs of a liver problem, including:

- tiredness
- loss of appetite
- pain in your right upper stomach-area
- dark urine
- yellowing of your skin or the white part of your eyes

The most common side effects of ELREXFIO include:

- tiredness
- injection site reaction, such as redness, itching, pain, bruising, rash, swelling, and tenderness
- diarrhea
- muscle and bone pain
- decreased appetite
- rash
- cough
- nausea
- fever

The most common severe abnormal lab test results with ELREXFIO include decreased white blood cells, red blood cells, and platelets.

Your healthcare provider may temporarily or permanently stop ELREXFIO if you have any of the side effects listed and they are severe. These are not all of the possible side effects of ELREXFIO.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is ELREXFIO?

ELREXFIO is a prescription medication used to treat adults with multiple myeloma who:

- have already received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody to treat their multiple myeloma, **and**
- their cancer has come back or did not respond to prior treatment

ELREXFIO was approved based on patient responses and durability of response. There are ongoing studies to confirm its clinical benefit. It is not known if ELREXFIO is safe and effective in children.

Please see full [Prescribing Information](#), including **BOXED WARNING**, and [Medication Guide](#).